Zheng Kun, Yao Shuo, Yao Wei, Li Qianxia, Wang Yali, Zhang Lili, Chen Xiuqiong, Xiong Huihua, Yuan Xianglin, Wang Yihua, Zou Yanmei, Xiong Hua
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom.
Front Genet. 2021 Nov 1;12:770134. doi: 10.3389/fgene.2021.770134. eCollection 2021.
Although ribosomal protein S6 kinases, 90 kDa, polypeptide 3 (, ) has been reported to play an important role in cancer cell proliferation, invasion, and migration, including breast cancer, its clinical implication in primary breast cancer patients is not well understood, and there were not many studies to explore the relationship between and breast cancer on a clinical level. A systematic series matrix file search uploaded from January 1, 2008 to November 31, 2017 was undertaken using ArrayExpress and Gene Expression Omnibus (GEO) databases. Search filters were breast cancer, RNA assay, and array assay. Files eligible for inclusion met the following criteria: a) sample capacity is over 100, b) tumor sample comes from unselected patient's primary breast tumor tissue, and c) expression of and any clinical parameters of patients were available from the files. We use median as the cutoff value to assess the association between the expression of and the clinical indexes of breast cancer patients. The meta-analysis identified 13 series matrix files from GEO database involving 3,122 samples that come from patients' primary breast cancer tissue or normal tissue. The expression of in tumor tissues is lower than that in normal tissues [odds ratio (OR), 0.54; 95% credible interval (CI), 0.44-0.67; Cochran's test = 0.14; = 41.7%]. Patients with a high expression of showed more favorable overall survival [hazard ratio (HR), 0.71; 95% CI, 0.49-0.94; Cochran's test = 0.95; = 0.0%] and less potential of distant metastasis (OR, 0.59; 95% CI, 0.41-0.87; Cochran's test = 0.88; = 0.0%) and lymph node infiltration (OR, 0.81; 95% CI, 0.65-0.998; Cochran's test = 0.09; = 42.8%). Besides, the expression of in luminal breast cancer is lower than Cochran's test = 0.06; = 63.5%). overexpression corresponded with higher histological grade (OR, 1.329; 95% CI, 1.03-1.721; Cochran's test = 0.69; = 0.0%). expression is also associated with estrogen receptor (ER) and age. The meta-analysis provides evidence that is a potential biomarker in breast cancer patients. The expression of is distinctive in different intrinsic subtypes of breast cancer, indicating that it may play an important role in specific breast cancer. Further study is needed to uncover the mechanism of in breast cancer. (website), identifier (registration number).
尽管据报道核糖体蛋白S6激酶90 kDa多肽3（ ）在癌细胞增殖、侵袭和迁移（包括乳腺癌）中发挥重要作用，但其在原发性乳腺癌患者中的临床意义尚未得到充分理解，且在临床层面探索 与乳腺癌之间关系的研究也不多。我们使用ArrayExpress和基因表达综合数据库（GEO）对2008年1月1日至2017年11月31日上传的系统系列矩阵文件进行了搜索。搜索筛选条件为乳腺癌、RNA检测和阵列检测。符合纳入标准的文件满足以下条件：a）样本量超过100；b）肿瘤样本来自未经选择的患者原发性乳腺肿瘤组织；c）文件中可获得 的表达及患者的任何临床参数。我们以中位数作为截断值来评估 的表达与乳腺癌患者临床指标之间的关联。荟萃分析从GEO数据库中确定了13个系列矩阵文件，涉及3122个来自患者原发性乳腺癌组织或正常组织的样本。 在肿瘤组织中的表达低于正常组织[优势比（OR），0.54；95%可信区间（CI），0.44 - 0.67； Cochr an检验 = 0.14； = 41.7%]。 高表达的患者总体生存率更优[风险比（HR），0.71；95% CI，0.49 - 0.94； Cochr an检验 = 0.95； = 0.0%]，远处转移潜力较小（OR，0.59；95% CI，0.41 - 0.87； Cochr an检验 = 0.88； = 0.0%），淋巴结浸润较少（OR, 0.81；95% CI，0.65 - 0.998； Cochr an检验 = 0.09； = 42.8%）。此外， 在管腔型乳腺癌中的表达低于 Cochr an检验 = 0.06； = 63.5%）。 过表达与更高的组织学分级相关（OR，1.329；95% CI，1.03 - 1.721； Cochr an检验 = 0.69； = 0.0%）。 的表达还与雌激素受体（ER）和年龄相关。荟萃分析提供了证据表明 是乳腺癌患者的潜在生物标志物。 在不同的乳腺癌内在亚型中的表达具有独特性，表明它可能在特定的乳腺癌中发挥重要作用。需要进一步研究以揭示其在乳腺癌中的作用机制。（网站），标识符（注册号） 。
需注意，原文中存在一些未明确写出的内容（用空格和逗号表示），翻译时保留了这些未明确内容的原样。你可根据实际情况进一步核对原文信息。
